thiazolyl blue has been researched along with Carcinoma, Neuroendocrine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sabra, MM; Sherman, EJ; Tuttle, RM; Yeh, T; Yeung, M | 1 |
1 other study(ies) available for thiazolyl blue and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Topics: Adolescent; Adult; Aged; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Cell Proliferation; Disease Progression; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Retrospective Studies; Tetrazolium Salts; Thiazoles; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2020 |